February 16, 2022 8:13am
Are the algorithmic “scalp hunters” eyeing Tuesday’s upsiders?
Pre-open indications: 5 BUYs, 5 SELLs and 1 Pimp/Pump/Promote
What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Only the facts … I ask questions and note the probabilities
Dow futures are DOWN -0.24% (-84 points), S&P futures are DOWN -0.29% (-13 points) and NASDAQ futures are DOWN -0.28% (-45 points)
U.S. stock index futures were down and slipping in pre-market trading Wednesday,
European markets inched higher as investors assessed the geopolitical outlook,
Asia-Pacific markets rose as tensions appeared to ease between Russia and Ukraine as investors reacted to weaker-than-expected Chinese inflation data.
Henry’omics:
Markets have been headline-driven in recent days.
The stock market bounced Tuesday, with the S&P 500 rebounding back above its 200-day line. The Dow closed just shy of its 200-day line. The S&P 500 and Nasdaq remain below their 21-day lines as well as their early February peaks. Getting above those early February highs, which also line up with the S&P 500's 50-day line, would be a sign of renewed market strength. <IBD>
Excellent quote, “U.S. stocks rallied on optimism that it doesn’t seem like Russia will invade Ukraine this week and despite another hot PPI report, as many on Wall Street are still not convinced the Fed will be as aggressive as some are calling for this year,” said Oanda’s Ed Moya. <CNBC>
Economic Data Docket: Retail sales data will be released at 8:30 a.m.; economists are expecting the print to show that sales rose 2.1% in January. That compares to a 1.9% decline in December. Minutes from the Fed’s January meeting, will be released at 2 p.m. ET.
If you didn’t remember what happen at Tuesday’s close, you won’t be prepared for today’s session,
RegMed Investors’ (RMi) closing bell: “a beautiful day in the sector’s neighborhood. Coming off a volatile Monday trading session” … https://www.regmedinvestors.com/articles/12302
Ebb and flow –
- February stats: 6 negative and 5 positive closes
- January stats: 1 holiday, 1 neutral, 13 negative and 6 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context:
Probabilities/ Potentials pre-open share pricing indication moves:
BUY:
CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Sage Therapeutics (SAGE), Ultragenyx (RARE),
SELL:
bluebird bio (BLUE), MiMedx (MDXG), UniQure NV (QURE), Regenxbio (RGNX), Verastem (VSTM)
Pimp/Pump and Promote:
Biostage (OTCQB: BSTG) closed flat on Tuesday with 200 shares traded after Monday’s flat with 1,899 shares traded after
Friday’s -$0.02 with 1,739 shares traded after Thursday’s +$0.60 to $4.58 with 2,841 shares traded, Wednesday’s -$0.61 with 4,030 shares traded, Tuesday’s +$0.05 to $4.59 with 1,293 shares traded and Monday’s +$0.55 with 2,311 shares traded,
The previous Friday’s +$0.22 with 305 shares traded, Thursday’s flat (-$0.00) with 3 shares traded, Wednesday’s -$0.53 with 502 shares traded, Tuesday’s +$0.40 with 1,088 shares traded, Monday’s flat with 11 shares traded,
And the preceding Friday’s +$0.05 to $3.90 with 3,362 shares traded, Thursday’s +$0.24 to $3.85 with 10,073 shares traded.
- WHO is BUYING these shares of a company with a 2-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?
- Also, by use of the pump/promote process; is BSTG preparing to register the outstanding private placement (PP) shares for a reverse to initiate an offering- they’re NOT going ANYWHERE without a cash inflow.
The BOTTOM LINE: I continue my skittishness regarding earnings’ reporting and the volatility in trading that usually precedes and follows releases.
Reiterating, “the cell and gene therapy sector’s relative valuation metrics suggest earnings reports are about to hit and I believe, hard.”
Investors have to recognize what kind of market we are in – VOLATILE with LOW VOLUME. Which gives us reasons to be cautious.
Earnings’ reporting:
- AxoGen AXGN) – Tuesday, 2/22
- Sage Therapeutics (SAGE), Thursday, 2/24
- Ionis Pharmaceuticals (IONS), Thursday, 2/24
- Athersys (ATHX), Tuesday, 3/15
Investors should focus on forward-looking guidance, last year’s operating losses i.e., spending and cash positions or runways!
I am NOT changing my position, “Brace for more choppiness as we move further into the month and the beginning of Q1/22 waiting for Q4 and FY21 numbers”.
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
WHY do I keep reporting on Biostage (BSTG): I WAS there to experience what occurred and saw the decay of transparency and more; it takes courage, resolve and patience to stay the course of asking the questions without response!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider their investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in FATE, CRS, securities referred to in this publication.
